It's How Medicine Should Be®

Font Size:

-A +A

Translate

French German Italian Portuguese Russian

DNA Methylation for Detection and Monitoring of Colorectal Cancer

Clinical Trial Protocol ID: 
09072204
Clinical Trial Investigator Name: 
Joshua Melson, MD

The primary objective of the study is to develop a plasma-based assay that allows for differentiation of patients with colorectal cancer (CRC) and advanced polyps from those with essentially normal colonic tissue. The most commonly used stool assays still have poor detection of adenomatous polyps, which leads to these types of assays having limited utility in reducing the actual incidence of CRC. We will obtain blood after patient enrollment and prior to initiation of any therapy for CRC.

Clinical Trial Eligibility Criteria: 

You may be eligible to participate in this study if you:

  • Are over age 18
  • Are able to give consent
  • Are already scheduled to undergo a clinically indicated (physician prescribed) endoscopic procedure at Rush, paid for by your insurance for your clinical evaluation
  • Provide a blood sample

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Contact Name: 
GI Clinical Trials
Contact Phone: 
(312) 942-3466